menu
    • menu

    Company profile for Supriya Lifescience

    NEW Drugs in Dev: 3
    Supriya Lifesciences-PSE
    News
    Supriya Lifescience Gets USFDA EIR For Lote Parshuram Site

    22 Apr 2026

    // EXPRESSPHARMA

    Supriya Lifescience Posts 11% YoY Q3 FY26 Growth

    14 Feb 2026

    // INDPHARMAPOST

    Supriya Lifescience Boosts Capacity And Global Readiness

    08 Jan 2026

    // EXPRESS PHARMA

    DATA COMPILATION
    #PharmaFlow

    Supriya Lifescience

    Contact Supplier

    Website

    BPI Europe

    Not Confirmed

    Book a meeting

    envelop Contact Supplier

    Latest Content by PharmaCompass

    https://www.youtube.com/embed/GcFi34PmHwc?si=yzKLaw9YooO6_7Hw

    EVENTS

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    INTERMEDIATES

    Key Products KEY PRODUCTS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass

    Supriya Lifesciences is a cGMP-compliant API manufacturing organization with a leadership position across key & niche products.

    Related CompaniesRelated Companies

    About

    Supriya Lifescience Limited, established in 1987 and headquartered in Mumbai, is a globally recognized, technology-driven manufacturer of APIs, CDMO, and formulations. Its facilities in Lote and Ambernath are approved by USFDA, EUGMP, Health Canada, and other agencies. Specializing in antihistamines, antiallergics, vitamins, anesthetics, and anti-asthmatics, Supriya serves 1500+ customers in over 86 countries, with 15+ USDMFs, 10+ CEPs, and a 1050 KL manufacturing capacity. Note: Product(s) under patent(s) are offered only for R&D purposes as per the Patent Act & not for commercial sale.

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Supriya Lifescienceindia-flag Flag
    Country
    Country
    India
    Address
    Address
    207/208 Udyog Bhavan, Sonawala Road, Goregoan [E], Mumbai – 400 063
    Telephone
    Telephone
    +91 2226860012
    Client Email
    Email
    supriya@supriyalifescience.com
    Client Website
    Website
    https://supriyalifescience.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/supriya-lifescience-limited/
    youtube
    YouTube
    https://www.youtube.com/@SupriyaLifescience/videos
    Twitter
    Twitter
    https://x.com/SupriyaLife/
    Contact Info
    Others

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    BPI Europe

    BPI Europe

    Not Confirmed

    envelop Contact Supplier

    BPI Europe

    Post an Enquiry

    Meeting

    Digital content read-more

    Explore the latest content creation from this company

    CORPORATE CONTENT #SupplierSpotlight

    Product List 2026

    read-more

      https://www.pharmacompass.com/pdf/party/content/supriya-lifescience-party-content-91048.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    Corporate Presentation

    read-more

      https://www.pharmacompass.com/pdf/party/content/supriya-lifescience-party-content-32145.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    FDF Product List 2024

    read-more

      https://www.pharmacompass.com/pdf/party/content/supriya-lifescience-party-content-57092.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    API Product List 2026

    read-more

      https://www.pharmacompass.com/pdf/party/content/supriya-lifescience-party-content-37984.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    GMP Certificate 2023

    read-more

      https://www.pharmacompass.com/pdf/party/content/supriya-lifescience-party-content-63376.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    DATA COMPILATION #PharmaFlow

    read-more
    read-more
    DMF filings rise 4.5% in Q3 2025; China holds lead, India records 20% growth in submissions

    DMF filings rise 4.5% in Q3 2025; China holds lead, India records 20% growth in submissions

    The third quarter (Q3) of 2025 witnessed a steady rise in Drug Master File (DMF) submissions to the US Food and Drug Administration (FDA). DMFs are used to provide confidential, detailed information about facilities, processes, or articles used in the manufacturing, processing, packaging, and storing of human drug productsA total of 323 Type II DMFs were submitted during this period, as opposed to 309 submissions in Q3 2024, marking an increase of 4.53 percent. This is the second highest number since 2018. In Q1 2025, 339 Type II filings were recorded.Across all DMF types (II, III, IV, and V), 479 DMFs were filed in Q3 2025, compared to 394 in Q3 2024, representing a 21.57 percent increase. Out of the 323 Type II DMFs submitted in Q3 2025, 40 had completed their review by the end of Q3, reflecting a processing lag between submission and review completion. View FDA DMF Filings in Q3 2025 (Power BI Dashboard, Free Excel Available)China maintains its lead while India posts double-digit growth in DMF submissions China and India continued to dominate DMF submissions in Q3 2025. China retained the top spot with 153 Type II DMFs, matching its submission count from Q3 2024. India recorded 131 DMFs, marking a 20.18 percent increase over 109 filings during the corresponding period last year.The United States stood a distant third with 17 filings, compared to 13 in Q3 2024. Among European nations, Italy recorded eight DMFs, doubling its 2024 tally. The Netherlands filed four, up from three. Spain submitted only one DMF, as against seven submitted in Q3 2024. Taiwan made three filings, up from one submitted in Q3 2024. Together, India, China and Taiwan accounted for about 88.9 percent of all Type II DMFs filed during the quarter. View FDA DMF Filings in Q3 2025 (Power BI Dashboard, Free Excel Available) China’s Suzhou Ryway Biotech tops corporate tally; India’s Hetero, Biophore followChina’s Suzhou Ryway Biotech led the company-wise tally with 12 DMF submissions in Q3 2025. The company had not filed any DMFs in Q3 2024.India’s Hetero Group followed with nine DMFs, maintaining the same number of filings as Q3 2024. Biophore India Pharmaceuticals ranked third with six DMFs, doubling its count from three last year.Other notable contributors include Sai Sreyas Pharmaceuticals (India) and Shanghai Haoyuan Chemexpress (China), with five DMFs each. Companies such as SNJ Group, Lunan Pharmaceutical, Allsino Pharmaceutical, Shankus Pharma, Jiangxi Xinganjiang Pharmaceutical, Sunpure Extracts, Lee Pharma, Umedica Laboratories, Linhai Tianyu Pharmaceutical and Maithri Drugs filed four DMFs each. View FDA DMF Filings in Q3 2025 (Power BI Dashboard, Free Excel Available) Olaparib, semaglutide lead molecular filings; Dr. Reddy’s files DMF for edoxaban & tucatinibDr. Reddy’s Laboratories also featured among key DMF filers in Q3 2025, submitting two DMFs — for edoxaban tosylate monohydrate and tucatinib copovidone. Edoxaban tosylate monohydrate (marketed as Savaysa by Daiichi Sankyo) is a prescription anticoagulant used to reduce the risk of stroke and to treat deep vein thrombosis and pulmonary embolism. Patent exclusivity for Savaysa extends until October 2026 in the United States, with no generic currently available.In terms of molecules, the highest number of DMFs were filed for olaparib, semaglutide, ruxolitinib phosphate, ferric carboxymaltose, and vismodegib, with three DMFs each in Q3 2025.Olaparib, sold by AstraZeneca under the brand name Lynparza, saw DMFs being filed by BDR Lifesciences and Intas Pharmaceuticals from India, and by ScinoPharm Taiwan during the quarter.Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist developed by Novo Nordisk, continued to draw strong interest from API manufacturers. DMFs for semaglutide were filed by three Chinese companies: Yangzhou Aurisco Pharmaceutical, Zhejiang Peptites Biotech, and Fujian Genohope Biotech.Ruxolitinib phosphate, marketed by Incyte as Jakafi, saw three DMFs. Three Indian companies — Alembic Pharmaceuticals, Valary Labs, and Devi Pharmatech — filed DMFs for this API in Q3 2025. Other molecules that received multiple DMF submissions include ferric carboxymaltose (used to treat iron-deficiency anemia) and vismodegib (an oral therapy for basal-cell carcinoma). View FDA DMF Filings in Q3 2025 (Power BI Dashboard, Free Excel Available) First-time DMF filings span 17 companies; India leads with nine first-time DMFs The quarter saw first-time DMF filings from 17 companies. India took a lead here with nine first-time DMF filings, followed by China (six), and the US (two).The DMF filings in this quarter included inclisiran sodium (filed by Aurisco Pharmaceutical of China), pacritinib citrate (by TAPI Nl B.V. of the Netherlands), and vosoritide (by Apicore LLC of the US).Out of the 19 first-time DMFs filed in Q3 2025, four completed their Generic Drug User Fee Amendments (GDUFA) review process during the quarter. View FDA DMF Filings in Q3 2025 (Power BI Dashboard, Free Excel Available) GDUFA fee for FY 2026: The FDA Generic Drug User Fee Amendments (GDUFA) is a law designed to speed access to safe and effective generic drugs to the public and reduce costs to the industry.Fee rates for fiscal year 2026 were published on July 30, 2025. FDA has revised fees under GDUFA III across all categories. While there is a slight increase in the DMF fee from US$ 95,084 in 2025 to US$ 102,584 in 2026, the ANDA fee has seen a sharp rise: from US$ 321,920 in 2025 to US$ 358,247 in 2026.FY 2025 and FY 2026 User Fee Rates Generic drug fee category Fees rates for FY 2025 Fees rates for FY 2026 Applications:     Abbreviated New Drug Application (ANDA) US$ 3,21,920 US$ 3,58,247 Drug Master File (DMF) US$ 95,084 US$ 1,02,584 Facilities:     Active Pharmaceutical Ingredient (API)—Domestic US$ 41,580 US$ 43,549 API—Foreign US$ 56,580 US$ 58,549 Finished Dosage Form (FDF)—Domestic US$ 2,31,952 US$ 2,38,943 FDF—Foreign US$ 2,46,952 US$ 2,53,943 Contract Manufacturing Organization (CMO)—Domestic US$ 55,668 US$ 57,346 CMO—Foreign US$ 70,668 US$ 72,346 GDUFA Program:     Large size operation generic drug applicant US$ 18,91,664 US$ 19,18,377 Medium size operation generic drug applicant US$ 7,56,666 US$ 7,67,351 Small business generic drug applicant US$ 1,89,166 US$ 1,91,838 Our viewFor several years prior to the pandemic, India had a lead in Type II DMF submissions. In recent years, China has surpassed India in DMF filings. But Q3 2025 numbers indicate that Indian drugmakers are fast catching up. Since DMFs establish trust in APIs from across the world, we feel this healthy competition between drugmakers from the two countries is good for the global pharmaceutical industry. 
    subscribeSubscribe
    ExcelExcel Download

    Impressions: 4188

    https://www.pharmacompass.com/radio-compass-blog/dmf-filings-rise-4-5-in-q3-2025-china-holds-lead-india-records-20-growth-in-submissions

    #PharmaFlow by PHARMACOMPASS
    13 Nov 2025
    Share Share
    Chinese FDA-registered generic facilities gain steam, India maintains lead with 396 facilities

    Chinese FDA-registered generic facilities gain steam, India maintains lead with 396 facilities

    Every year, the US Food and Drug Administration (FDA) publishes the user fee amounts it will collect from manufacturers of pharmaceuticals, generic drugs, biosimilars and medical devices in the coming financial year. The fee for fiscal year 2025 under the Generic Drug User Fee Act (GDUFA) was published on July 31, 2024.The GDUFA, established in 2012, authorizes FDA to assess and collect fees from drug manufacturers to expedite the delivery of safe, high-quality, and affordable generic drugs to the American public.The FDA’s facility payments list under GDUFA reveals that as of November 14, 2024, 1,397 facilities had paid their registration fees for financial year 2025. Of these facilities, 707 or 50.6 percent are active pharmaceutical ingredients (API) facilities, 405 or 29 percent are finished dosage forms (FDF) facilities, 69 (4.9 percent) are facilities that produce both APIs and FDFs, and 216 (15.5 percent) are contract manufacturing services (CMO) sites.Teva Pharmaceuticals, with 29 facility registrations, led the list of companies, followed by Aurobindo Pharma, Sun Pharma, and Dr. Reddy's Laboratories. Fiscal year Facility Registrations 2016 1,425 2017 1,442 2018 1,269 2019 1,286 2020 1,300 2021 1,340 2022 1,385 2023 1,394 2024 1,447 2025 1,397  Generic Drug Facilities Registered with the US FDA for FY2025 (Free Excel Available)India continues to lead with 396 facilities, US and China follow India maintains its dominance in total facility registrations with the FDA, registering 396 facilities for FY2025. This includes 214 API facilities, 135 FDF facilities, 21 facilities engaged in both API and FDF activities, and 26 CMO facilities.The United States holds the second position with 328 facilities, while China strengthened its third position with 197 facilities.With 214 API facilities, India continues to have the largest share of API manufacturing sites, outmatching the combined total of China (128) and the US (83), which together account for 211 facilities. Among European manufacturers, Italy leads with 59 API manufacturing sites, followed by Spain (30) and Germany (25).The US has maintained its lead in FDF facilities with 143 sites, followed closely by India with 135 sites and China with 45 sites. Country API FDF Both CMO Total India 214 135 21 26 396 US 83 143 13 89 328 China 128 45 12 12 197 Italy 59 3 2 19 83 Germany 25 4 1 15 45 Spain 30 9 1 4 44 Canada 7 17   13 37 Taiwan 9 6 5 4 24 Switzerland 15 4   4 23 France 16     6 22 Japan 18   1   19 United Kingdom 12 1   2 15 Mexico 9 1   1 11 Ireland 5 5   1 11   Generic Drug Facilities Registered with the US FDA for FY2025 (Free Excel Available) GDUFA III user fee rates increase across categories for FY25The GDUFA, which was reauthorized on September 30, 2022 (as GDUFA III), continues with provisions that will last until September 30, 2027. In July 2024, the FDA published updated user fee rates for FY2025.The facility fees have seen increases across all categories. API facility fees increased by 3 percent for domestic sites (to US$ 41,580) and 2 percent for foreign sites (to US$ 56,580). FDF facility fees rose by 5 percent for both domestic (to US$ 231,952) and foreign sites (to US$ 246,952). CMO facility fees increased by 5 percent for domestic sites (to US$ 55,668) and 4 percent for foreign sites (to US$ 70,668).Additionally, the fee for large-, medium- and small-sized drug applicants has increased by over 9 percent, compared to the 7 percent increase seen in 2023. Generic Drug Facilities Registered with the US FDA for FY2025 (Free Excel Available) China leads new facility registrations as FDA records 41 new units in FY25Out of the total 1,397 facilities registered for FY2025, 41 were new registrations (going by Facility FDA Establishment Identifier numbers). China led the way with 13 new facilities, followed closely by India with 11 new facilities, while the US secured the third position with eight new facilities.The new registrations included 15 API facilities, 13 CMO facilities, 12 FDF facilities, and one facility engaged in both API and FDF activities. Chinese companies dominated the new FDF registrations with six facilities: Chengdu Shuode Pharma, Chengdu Suncadia Medicine, Cipla (Jiangsu), GE Healthcare (Shanghai), Luoxin Aurovitas Pharma (Chengdu), and Zhejiang Xianju Pharma.India added two new FDF facilities through Eugia Steriles and Zydus Pharma. Malaysia registered two FDF facilities through Novugen Pharma and Novugen Oncology, while Turkey’s Insud Pharma subsidiary Exeltis and US’ RK Pharma registered one FDF facility each.The 13 new CMO facilities included, Acme Generics, Emcure, Esjay Pharma, Fordoz Pharma, Fourrts Laboratories, Laboratoires KABS, PharmaMax, Quality Packaging Specialists International, Ritsa Pharma, Shanghai Aucyun Pharma, Sichuan Huiyu Pharma, Taejoon Pharm, and Tubilux Pharma.In the API category, the 15 new registrations included Acharya Chemicals, Hainan Poly Pharma, CBL Patras, EUROAPI, Hybio Pharma, Medilux Laboratories, Metrochem API, Purolite, Chengdu Easton Biopharma, Sionc Pharma, Smithfield Bioscience, Xttrium Laboratories, Zhejiang Hengkang Pharma, Moehs Iberica and Shilpa Pharma. Armstrong Pharmaceuticals registered the sole facility for both APIs and FDFs.So far, 92 facilities have not renewed their registration. Among these was a facility owned by Sandoz subsidiary Eon Labs in Wilson, North Carolina (US), which is permanently closed. In fact, the geographical distribution of non-renewals shows that 30 facilities were from the US, while India and China accounted for 14 and nine non-renewals respectively. Generic Drug Facilities Registered with the US FDA for FY2025 (Free Excel Available) Our viewThe FY 2025 GDUFA facility registration data indicates a continued strong presence of Indian manufacturers in the US generic drug market, particularly in API production. However, China's leadership in new facility registrations, especially in FDF manufacturing, suggests that the global generic drug supply chain landscape may evolve considerably in the coming years. 
    subscribeSubscribe
    ExcelExcel Download

    Impressions: 15977

    https://www.pharmacompass.com/radio-compass-blog/chinese-fda-registered-generic-facilities-gain-steam-india-maintains-lead-with-396-facilities

    #PharmaFlow by PHARMACOMPASS
    21 Nov 2024
    Share Share

    NEWS #PharmaBuzz

    read-more
    read-more
    Supriya Lifescience Gets USFDA EIR For Lote Parshuram Site
    Supriya Lifescience Gets USFDA EIR For Lote Parshuram Site

    22 Apr 2026

    // EXPRESSPHARMA

    https://www.expresspharma.in/supriya-lifescience-receives-usfda-eir-with-vai-classification-for-lote-parshuram-facility/

    EXPRESSPHARMA
    22 Apr 2026
    Share Share
    Supriya Lifescience Posts 11% YoY Q3 FY26 Growth
    Supriya Lifescience Posts 11% YoY Q3 FY26 Growth

    14 Feb 2026

    // INDPHARMAPOST

    https://www.indianpharmapost.com/news/supriya-lifescience-delivers-robust-q3-fy26-performance-with-11-yoy-revenue-growth-19102

    INDPHARMAPOST
    14 Feb 2026
    Share Share
    Supriya Lifescience Boosts Capacity And Global Readiness
    Supriya Lifescience Boosts Capacity And Global Readiness

    08 Jan 2026

    // EXPRESS PHARMA

    https://www.expresspharma.in/supriya-lifescience-ramps-up-capacity-and-global-readiness-for-next-phase-of-growth/

    EXPRESS PHARMA
    08 Jan 2026
    Share Share
    Supriya Lifescience Targets Rs 1,600-Crore Revenue In 3 Years
    Supriya Lifescience Targets Rs 1,600-Crore Revenue In 3 Years

    22 Dec 2025

    // ECONOMICTIMES

    https://www.news18.com/business/supriya-lifescience-targets-rs-1600-crore-revenue-in-3-years-details-here-ws-l-9785859.html

    ECONOMICTIMES
    22 Dec 2025
    Share Share
    Supriya Lifescience Aims For Rs 1,600Cr Revenue In 3 Years
    Supriya Lifescience Aims For Rs 1,600Cr Revenue In 3 Years

    17 Dec 2025

    // ECONOMICTIMES

    https://economictimes.indiatimes.com/industry/healthcare/biotech/healthcare/supriya-lifescience-targets-rs-1600-cr-revenue-in-three-years-on-capacity-expansion/articleshow/126004157.cms

    ECONOMICTIMES
    17 Dec 2025
    Share Share
    Supriya Lifescience Expands Lote Facility With New Module E
    Supriya Lifescience Expands Lote Facility With New Module E

    25 Nov 2025

    // EXPRESSPHARMA

    https://www.expresspharma.in/supriya-lifescience-ramps-up-capacity-of-its-lote-facility-with-new-module-e/

    EXPRESSPHARMA
    25 Nov 2025
    Share Share

    KEY PRODUCTS

    read-more
    read-more

    TOP RANKED SUPPLIER FOR:

    Sponsored Ads.
    full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view

    Inspections and registrations

    Check the inspections & registration from this company

    ABOUT THIS PAGE

    Contact Supriya Lifescience and get a quotation

    Supriya Lifescience is a supplier offers 67 products (APIs, Excipients or Intermediates).

    Find Brompheniramine Maleate bulk with DMF, CEP, WC offered by Supriya Lifescience

    Find Diphenhydramine Hydrochloride bulk with DMF, CEP, WC offered by Supriya Lifescience

    Find Esketamine Hydrochloride bulk with DMF, CEP, WC offered by Supriya Lifescience

    Find Ketamine Hydrochloride bulk with DMF, CEP, WC offered by Supriya Lifescience

    Find Pheniramine Maleate bulk with DMF, CEP, WC offered by Supriya Lifescience

    Find Pyrilamine Maleate bulk with DMF, CEP, WC offered by Supriya Lifescience

    Find Salbutamol Sulphate bulk with DMF, CEP, WC offered by Supriya Lifescience

    Find Tramadol Hydrochloride bulk with DMF, CEP, WC offered by Supriya Lifescience

    Find Allopurinol bulk with DMF, WC offered by Supriya Lifescience

    Find Bisoprolol Fumarate bulk with DMF, WC offered by Supriya Lifescience

    Find Cetirizine Dihydrochloride bulk with DMF, WC offered by Supriya Lifescience

    Find Chlorpheniramine Maleate bulk with DMF, WC offered by Supriya Lifescience

    Find Dextromethorphan Hydrobromide bulk with DMF, WC offered by Supriya Lifescience

    Find Methylcobalamin bulk with DMF, WC offered by Supriya Lifescience

    Find Pentoxifylline bulk with CEP, WC offered by Supriya Lifescience

    Find Riboflavin 5 Phosphate Sodium bulk with DMF, JDMF offered by Supriya Lifescience

    Find Tramadol Hydrochloride bulk with DMF, CEP offered by Supriya Lifescience

    Find Allopurinol bulk with WC offered by Supriya Lifescience

    Find Bisoprolol Fumarate bulk with WC offered by Supriya Lifescience

    Find Brompheniramine Maleate bulk with WC offered by Supriya Lifescience

    Find Bupropion Hydrochloride bulk with WC offered by Supriya Lifescience

    Find Cetirizine Dihydrochloride bulk with WC offered by Supriya Lifescience

    Find Chlorpheniramine bulk with CEP offered by Supriya Lifescience

    Find Chlorpheniramine Maleate bulk with WC offered by Supriya Lifescience

    Find Dexbrompheniramine Maleate bulk with WC offered by Supriya Lifescience

    Find Dexchloropheniramine Maleate bulk with WC offered by Supriya Lifescience

    Find Dextromethorphan Hydrobromide bulk with WC offered by Supriya Lifescience

    Find Diphenhydramine Hydrochloride bulk with WC offered by Supriya Lifescience

    Find Hydroxocobalamin bulk with DMF offered by Supriya Lifescience

    Find Ketamine Hydrochloride bulk with WC offered by Supriya Lifescience

    Find Midazolam bulk with DMF offered by Supriya Lifescience

    Find Nicorandil bulk with WC offered by Supriya Lifescience

    Find Pyrilamine Maleate bulk with WC offered by Supriya Lifescience

    Find Salbutamol Sulphate bulk with WC offered by Supriya Lifescience

    Find Sevoflurane bulk with DMF offered by Supriya Lifescience

    Find Aminophylline bulk offered by Supriya Lifescience

    Find Amphetamine Sulfate bulk offered by Supriya Lifescience

    Find ATS-8 bulk offered by Supriya Lifescience

    Find Benserazide Hydrochloride bulk offered by Supriya Lifescience

    Find Cetirizine bulk offered by Supriya Lifescience

    Find Cetirizine Dihydrochloride bulk offered by Supriya Lifescience

    Find Chlorpheniramine Maleate bulk offered by Supriya Lifescience

    Find Colchicine bulk offered by Supriya Lifescience

    Find Daridorexant bulk offered by Supriya Lifescience

    Find Desflurane bulk offered by Supriya Lifescience

    Find Dexchloropheniramine Maleate bulk offered by Supriya Lifescience

    Find Dexmedetomidine Hydrochloride bulk offered by Supriya Lifescience

    Find Gadobutrol bulk offered by Supriya Lifescience

    Find Hydroxocobalamin Acetate bulk offered by Supriya Lifescience

    Find Hydroxocobalamin Hydrochloride bulk offered by Supriya Lifescience

    Find Ibuprofen Piconol bulk offered by Supriya Lifescience

    Find Iohexol bulk offered by Supriya Lifescience

    Find Isoflurane bulk offered by Supriya Lifescience

    Find Lidocaine bulk offered by Supriya Lifescience

    Find Lidocaine Hydrochloride bulk offered by Supriya Lifescience

    Find Lisdexamfetamine Dimesylate bulk offered by Supriya Lifescience

    Find Methylcobalamin bulk offered by Supriya Lifescience

    Find Methylphenidate bulk offered by Supriya Lifescience

    Find Midazolam Hydrochloride bulk offered by Supriya Lifescience

    Find Midazolam Maleate bulk offered by Supriya Lifescience

    Find Pentobarbital Sodium bulk offered by Supriya Lifescience

    Find Propofol bulk offered by Supriya Lifescience

    Find Remimazolam Besylate bulk offered by Supriya Lifescience

    Find Semaglutide bulk offered by Supriya Lifescience

    Find Sildenafil Citrate bulk offered by Supriya Lifescience

    Find Tramadol Hydrochloride bulk offered by Supriya Lifescience

    Find Trimebutine Maleate bulk offered by Supriya Lifescience

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search